Prakash Peddi, MD
Hematology & Oncology · Shreveport, LANPI 1093926446
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $307,448 of the $405,255 with a category attached, or 75.9%. 60 manufacturers reported payments, led by AstraZeneca at 27.4% of the total. 2025 is the largest year on record at $141,468, 7.8 times the $18,059 reported in 2019. Among hematology & oncology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,220 payments — averaging $332.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$111K
- Gilead$104K
- Daiichi Sankyo Inc.$69K
- Stemline Therapeutics Inc.$65K
- Novartis$29K
- Seagen Inc.$14K
- plus $14K from 54 others
Across 5 payments — averaging $53,216 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$236K
- AstraZeneca$29K
- Eli Lilly$1K
What the payments were for
- Consulting fees$33,3118%
- Speaking & faculty fees$307,44876%
- Travel & lodging$34,0748%
- Food & beverage$24,8876%
- Education$1,1240%
- Gifts$8140%
- Other$3,5981%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$405,255 in reported general payments places this provider in the 95th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kisqali Femara Co-PackRibociclib Succinate/Letrozole | 55 | $934,735 |
| KisqaliRibociclib Succinate | 68 | $928,001 |
| VerzenioAbemaciclib | 32 | $461,639 |
| Abiraterone Acetate | 81 | $322,041 |
| ErleadaApalutamide | 23 | $254,656 |
| SprycelDasatinib | 17 | $236,478 |
| IbrancePalbociclib | 15 | $212,573 |
| RevlimidLenalidomide | 11 | $134,548 |
| LonsurfTrifluridine/Tipiracil Hcl | 18 | $133,268 |
| DopteletAvatrombopag Maleate | 12 | $89,944 |
| Imatinib Mesylate | 26 | $65,912 |
| EliquisApixaban | 54 | $31,072 |
| Letrozole | 851 | $15,834 |
| XareltoRivaroxaban | 13 | $14,880 |
| VeozahFezolinetant | 20 | $10,407 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisKisqali | $28,503 | $928,00168 claims |
| Lilly USA, LLCVerzenio | $177 | $461,63932 claims |
| Johnson & JohnsonErleada, Xarelto | $1,211 | $269,53636 claims |
| PfizerIbrance, Eliquis | $549 | $243,64569 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $457 | $236,47817 claims |
| Bristol Myers SquibbRevlimid | $538 | $134,54811 claims |
| Taiho Oncology, Inc.Lonsurf | $77 | $133,26818 claims |
| Astellas Pharma US IncVeozah | $539 | $10,40720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 183 hematology & oncology providers in Louisiana.
Other hematology & oncology in Shreveport
- Kevin GallagherShreveport$145K
- Maxwell McDonaldShreveport$123K
- Kirtan KotichaShreveport$45K
- Tharwat GhattasShreveport$25K
- Joyce FeaginShreveport$19K
- Richard MansourShreveport$16K
- Kavitha BeedupalliShreveport$15K
- Steven BoniolShreveport$14K
- Gary BurtonShreveport$10K
- Hana SafahBaton Rouge$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.